NK - NantKwest (NK) shares climb on approval of ImmunityBio merger

NantKwest (NK) gains 7% premarket after its stockholders approved the proposal related to the pending merger with ImmunityBio.The transaction is expected to close today.The combined company will assume the ImmunityBio name and its common shares are expected to trade on Nasdaq under the symbol “IBRX” commencing on March 10.The merger will create an immunotherapy and cell therapy company focused on oncology and infectious disease by orchestrating the innate (NK) and adaptive (T cell) immune system.Yesterday, the companies began dosing in global COVID-19 vaccine trials.In December 2020, NantKwest, ImmunityBio inked merger deal.

For further details see:

NantKwest (NK) shares climb on approval of ImmunityBio merger